Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
163.71
+0.58 (0.36%)
At close: Mar 28, 2025, 4:00 PM
163.70
-0.01 (-0.01%)
After-hours: Mar 28, 2025, 8:00 PM EDT
Johnson & Johnson Revenue
In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth. Johnson & Johnson had revenue of $22.52B in the quarter ending December 29, 2024, with 5.26% growth.
Revenue (ttm)
$88.82B
Revenue Growth
+4.30%
P/S Ratio
4.44
Revenue / Employee
$643,164
Employees
138,100
Market Cap
394.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionJNJ News
- 11 hours ago - Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade) - Seeking Alpha
- 15 hours ago - Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case - Reuters
- 1 day ago - Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. - Market Watch
- 2 days ago - Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns - Seeking Alpha
- 2 days ago - RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer - PRNewsWire
- 2 days ago - New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG) - PRNewsWire
- 4 days ago - BofA reveals stocks with a history of steady returns amid market volatility - Invezz
- 6 days ago - 2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth Portfolio - Seeking Alpha